SCHEMBL13496136

SCHEMBL13496136

CON(C)C(=O)c1cccc2cccc(CO)c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.38
MAPK8 P45983 1/20 0.36
MAPK9 P45984 1/20 0.36
MAPK10 P53779 1/20 0.36
HTR2A P28223 1/20 0.35
ATM Q13315 1/20 0.34
TDP1 Q9NUW8 2/20 0.33
TRPM8 Q7Z2W7 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
HSD17B10 Q99714 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
CLK1 P49759 1/20 0.33
DYRK1A Q13627 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
PPARG P37231 1/20 0.33
LPAR5 Q9H1C0 1/20 0.33
CACNA1B Q00975 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13496084 0.83 POLB (0.40) POLBHTR2ATDP1L3MBTL1HSD17B10
SCHEMBL4610471 0.83 LMNA (0.46) POLBMAPK8MAPK9MAPK10TRPM8
SCHEMBL13496221 0.80 FTO (0.39) POLBATMTDP1L3MBTL1MEN1
SCHEMBL13496228 0.80 KDM4E (0.31) TDP1TRPM8HSD17B10KDM4EMAPT
SCHEMBL1515779 0.76 NR4A1 (0.52) POLBTDP1MEN1KMT2AHSD17B10
SCHEMBL15608464 0.76 HPGD (0.40) POLBTDP1MEN1KMT2AMAPT
SCHEMBL13496234 0.75 SLC6A3 (0.43) MEN1KMT2ACLK1DYRK1ADYRK1B
SCHEMBL13806872 0.74 ALDH1A1 (0.42) KMT2AHSD17B10
SCHEMBL14889791 0.74 HSD17B10 (0.60) POLBTDP1L3MBTL1MEN1KMT2A
SCHEMBL5880146 0.72 ALDH1A1 (0.44) POLBTDP1TRPM8L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329377-B2 Imide compound and chemically amplified resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-12-11 US disclosed
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same IGF1R, CCNA1, MYC POLB 356/4885MAPK8 2414/4885MAPK9 2422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.